Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.

Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D.

Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.

PMID:
31494037
2.

Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues.

Conforti A, Schettini F, Vallone R, Di Rella F, De Rosa P, De Santo I, Giuliano M, Arpino G, Lauria R, De Placido S, Caputo R, De Laurentiis M, Nazzaro G, De Placido G, Locci M, Alviggi C.

Breast J. 2019 Jul 23. doi: 10.1111/tbj.13474. [Epub ahead of print] No abstract available.

PMID:
31338934
3.

Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report.

Pirozzi A, Riccardi F, Arpino G, Mocerino C, Campione S, Molino C, Cartenì G.

Medicine (Baltimore). 2019 Jul;98(29):e16508. doi: 10.1097/MD.0000000000016508.

4.

Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction.

Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S, Trimarco B, Lancellotti P, Arpino G, Galderisi M.

Eur Heart J Cardiovasc Imaging. 2019 Jul 21. pii: jez194. doi: 10.1093/ehjci/jez194. [Epub ahead of print]

PMID:
31326981
5.

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L.

Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5.

6.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28.

PMID:
30739312
7.

Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F.

Cancer Treat Rev. 2019 Feb;73:73-83. doi: 10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Review.

PMID:
30682661
8.

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.

Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L.

Front Oncol. 2018 Dec 12;8:608. doi: 10.3389/fonc.2018.00608. eCollection 2018. Review.

9.

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.

Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, Guarneri V, Marchetti P, Puglisi F.

BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.

10.

Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells.

Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM.

Mol Cancer Res. 2019 Feb;17(2):628-641. doi: 10.1158/1541-7786.MCR-17-0324. Epub 2018 Sep 21.

PMID:
30242055
11.

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.

Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G; PERTAIN Study Group.

J Clin Oncol. 2018 Oct 1;36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863. Epub 2018 Aug 14.

PMID:
30106636
12.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F.

Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12.

13.

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G.

Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11. Review.

14.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214.

15.

Visualization of Membrane Pore in Live Cells Reveals a Dynamic-Pore Theory Governing Fusion and Endocytosis.

Shin W, Ge L, Arpino G, Villarreal SA, Hamid E, Liu H, Zhao WD, Wen PJ, Chiang HC, Wu LG.

Cell. 2018 May 3;173(4):934-945.e12. doi: 10.1016/j.cell.2018.02.062. Epub 2018 Apr 5.

16.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
17.

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.

Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2.

18.

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.

Pensabene M, Stanzione B, Cerillo I, Ciancia G, Cozzolino I, Ruocco R, Condello C, Di Lorenzo G, Giuliano M, Forestieri V, Arpino G, De Placido S, Lauria R.

BMC Cancer. 2018 Feb 6;18(1):146. doi: 10.1186/s12885-018-4054-x. Review.

19.

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.

Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G.

Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29.

20.

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G.

Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.

21.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G.

Breast. 2018 Apr;38:86-91. doi: 10.1016/j.breast.2017.12.012. Epub 2018 Jan 4.

22.

Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study.

Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, Lauria R, De Santo I, Conforti A, Gallo A, Nazzaro G, De Placido S, Locci M, De Placido G.

Menopause. 2018 Jun;25(6):657-662. doi: 10.1097/GME.0000000000001053. Erratum in: Menopause. 2018 Oct;25(10):1169.

PMID:
29286986
23.

PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?

Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M.

Breast Care (Basel). 2017 Oct;12(5):290-294. doi: 10.1159/000481657. Epub 2017 Oct 19. Review.

24.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F.

Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.

PMID:
29182361
25.

The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?

Buono G, Schettini F, Perri F, Arpino G, Bianco R, Criscitiello C, De Placido S, Giuliano M.

Anticancer Agents Med Chem. 2018;18(6):832-836. doi: 10.2174/1871520617666171103105247. Review.

PMID:
29110627
26.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.

Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.

27.

Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study.

Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, Bruzzese D, De Placido S, Arpino G.

Clin Breast Cancer. 2017 Nov;17(7):559-563. doi: 10.1016/j.clbc.2017.05.007. Epub 2017 May 19.

PMID:
28601383
28.

2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.

Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G, Trimarco B, De Placido S, Galderisi M.

Eur Heart J Cardiovasc Imaging. 2017 May 1;18(8):930-936. doi: 10.1093/ehjci/jex033.

PMID:
28379383
29.

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.

De Placido S, De Angelis C, Giuliano M, Pizzi C, Ruocco R, Perrone V, Bruzzese D, Tommasielli G, De Laurentiis M, Cammarota S, Arpino G, Arpino G.

Br J Cancer. 2017 Mar 14;116(6):821-827. doi: 10.1038/bjc.2017.24. Epub 2017 Feb 7.

30.

Tumor characteristics and prognosis in familial breast cancer.

Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.

BMC Cancer. 2016 Nov 29;16(1):924.

31.

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F.

Breast. 2017 Feb;31:114-120. doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9.

32.

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

Schettini F, Giuliano M, De Placido S, Arpino G.

Cancer Treat Rev. 2016 Nov;50:129-141. doi: 10.1016/j.ctrv.2016.09.004. Epub 2016 Sep 12. Review.

PMID:
27665540
33.

Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.

Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, De Placido S, Nazzaro G, Locci M, De Placido G.

Menopause. 2016 Oct;23(10):1108-13. doi: 10.1097/GME.0000000000000672.

PMID:
27648595
34.

Actin dynamics provides membrane tension to merge fusing vesicles into the plasma membrane.

Wen PJ, Grenklo S, Arpino G, Tan X, Liao HS, Heureaux J, Peng SY, Chiang HC, Hamid E, Zhao WD, Shin W, Näreoja T, Evergren E, Jin Y, Karlsson R, Ebert SN, Jin A, Liu AP, Shupliakov O, Wu LG.

Nat Commun. 2016 Aug 31;7:12604. doi: 10.1038/ncomms12604.

35.

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.

Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.

BMC Cancer. 2016 Jul 4;16:375. doi: 10.1186/s12885-016-2414-y.

36.

Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.

Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LS, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G.

Curr Res Transl Med. 2016 Jan-Mar;64(1):15-20. doi: 10.1016/j.retram.2016.01.004. Epub 2016 Mar 2.

PMID:
27140595
37.

Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.

Arpino G, Marmé F, Cortés J, Ricevuto E, Leonard R, Llombart-Cussac A.

Crit Rev Oncol Hematol. 2016 Mar;99:81-90. doi: 10.1016/j.critrevonc.2015.10.007. Epub 2015 Oct 28. Review.

PMID:
26712590
38.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
39.

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.

Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S.

Breast Cancer Res Treat. 2015 Nov;154(1):127-32. doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30.

40.

Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?

Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M.

Eur J Surg Oncol. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review.

PMID:
26238477
41.

Features of aggressive breast cancer.

Arpino G, Milano M, De Placido S.

Breast. 2015 Oct;24(5):594-600. doi: 10.1016/j.breast.2015.06.001. Epub 2015 Jul 3. Review.

42.

Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?

Fusco F, Arcaniolo D, Creta M, Piccinocchi G, Arpino G, Laringe M, Piccinocchi R, Longo N, Verze P, Mangiapia F, Imperatore V, Mirone V.

World J Urol. 2015 May;33(5):685-9. doi: 10.1007/s00345-014-1460-9. Epub 2014 Dec 10.

PMID:
25491675
43.

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.

Arpino G, De Placido S, De Angelis C.

Anticancer Drugs. 2015 Jan;26(1):117-22. doi: 10.1097/CAD.0000000000000159.

44.

[Role of intensive medical training on Law 38 to improve pain management in primary care].

Mammucari M, Muscas F, Arpino G, Aronica A, Russo P, Visconti M.

Recenti Prog Med. 2014 Apr;105(4):159-65. doi: 10.1701/1459.16129. Italian.

PMID:
24770542
45.

Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network.

Pizzi C, Arpino G, Acampora G, Aiello N, DE Rosa A, Diaferia I, DI Nunzio A, Fragna G, Franco A, Russo M, Sansone F, Scarpati C, Spinuso A, Arpino G, Luce A, Tommasielli G, Caraglia M, DE Placido S.

Mol Clin Oncol. 2013 Jul;1(4):726-732. Epub 2013 Apr 4.

46.

Role of vesicular nucleotide transporter VNUT (SLC17A9) in release of ATP from AR42J cells and mouse pancreatic acinar cells.

Haanes KA, Kowal JM, Arpino G, Lange SC, Moriyama Y, Pedersen PA, Novak I.

Purinergic Signal. 2014 Sep;10(3):431-40. doi: 10.1007/s11302-014-9406-7. Epub 2014 Feb 2.

47.

Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response.

Di Cosimo S, Arpino G, Generali D.

Breast. 2014 Apr;23(2):188-92. doi: 10.1016/j.breast.2013.12.005. Epub 2014 Jan 4. Review.

48.

Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.

De Angelis C, Milano M, Gargiulo P, Stanzione B, Forestieri V, Lauria R, Pensabene M, D'Arco F, De Placido S, Arpino G.

Tumori. 2013 May-Jun;99(3):e131-3. doi: 10.1700/1334.14822.

PMID:
24158083
49.

Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis.

Crispo A, Barba M, Malvezzi M, Arpino G, Grimaldi M, Rosso T, Esposito E, Sergi D, Ciliberto G, Giordano A, Montella M.

Cancer Biol Ther. 2013 Dec;14(12):1113-22. doi: 10.4161/cbt.26425. Epub 2013 Sep 9.

50.

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

Montemurro F, Di Cosimo S, Arpino G.

Ann Oncol. 2013 Nov;24(11):2715-24. doi: 10.1093/annonc/mdt287. Epub 2013 Aug 1. Review.

PMID:
23908178

Supplemental Content

Loading ...
Support Center